Septerna (NASDAQ:SEPN) Stock

SEPTERNA INC

Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna Inc

<p>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) reported quarterly losses of $(0.14) per share. This is a 63.16 percent increase over losses of $(0.38) per share from the same period last year.  The company reported $11.30 million in sales this quarter.</p>


Earnings

News

IVVD

Invivyd Q1 EPS $(0.14) Up From $(0.38) YoY, Sales $11.30M Up from 0 YoY

<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td colspan="6">Second quarter</td>
<td colspan="3">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="6">The Company's second quarter fiscal 2026 guidance is based on Q2 FY25 net sales of $167.8 billion.</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">Consolidated metric</td>
<td colspan="3">Q2 FY26</td>
<td colspan="3">&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">Net sales (cc)</td>
<td colspan="3">
<p>Increase 3.5% to 4.5%</p>
<p>•Including approximately 20 bps tailwind from acquisition of VIZIO</p>
</td>
<td colspan="3">&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td colspan="3">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure></p>


Guidance

Walmart Sees Q2 Sales $173.673B-$175.350B vs $175.21B Est

<p>Bragg Gaming Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#TSX">BRAG</a>) reported quarterly losses of $(0.11) per share. This is a 37.5 percent decrease over losses of $(0.08) per share from the same period last year.  The company reported $25.50 million in sales this quarter. This is a 7.11 percent increase over sales of $23.81 million the same period last year.</p>


TSX:BRAG

Bragg Gaming Group Q1 EPS Euros(0.11) Down From $(0.08) YoY, Sales Euros25.50M Up From Euros23.81M YoY

<p>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) reported quarterly losses of $(15.96) per share which missed the analyst consensus estimate of $(14.08) by 13.35 percent. This is a 13.64 percent increase over losses of $(18.48) per share from the same period last year.  The company reported quarterly sales of $13.64 million which missed the analyst consensus estimate of $13.99 million by 2.49 percent.  This is a 21.95 percent decrease over sales of $17.48 million the same period last year.</p>


Earnings Misses

VERO

Venus Concept Q1 Adj. EPS $(15.96) Misses $(14.08) Estimate, Sales $13.64M Miss $13.99M Estimate

<p>Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.01) by 1100 percent. This is a 33.33 percent decrease over losses of $(0.09) per share from the same period last year.  The company reported quarterly sales of $26.82 million which beat the analyst consensus estimate of $26.75 million by 0.28 percent.  This is a 3.72 percent increase over sales of $25.86 million the same period last year.</p>


Earnings Beats

BRAG

Bragg Gaming Group Q1 EPS $(0.12) Misses $(0.01) Estimate, Sales $26.82M Beat $26.75M Estimate

<p>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year.  The company reported quarterly sales of $2.75 million which missed the analyst consensus estimate of $5.84 million by 52.84 percent.  This is a 70.21 percent decrease over sales of $9.24 million the same period last year.</p>


MRSN

Mersana Therapeutics Q1 EPS $(0.19), Inline, Sales $2.75M Miss $5.84M Estimate

<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td colspan="3">Fiscal year 2026</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td colspan="3">The Company's fiscal year guidance is based on the following FY25 figures: Net sales: $674.5 billion, adjusted operating income1: $29.5 billion, and adjusted EPS1: $2.51.</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Consolidated metric</td>
<td>Original from 2.20.2025</td>
<td>As of 5.15.2025</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Net sales (cc)</td>
<td>
<p>Increase 3.0% to 4.0%</p>
<p>•Including approximately 20 bps headwind from lapping leap year</p>
<p>•Including approximately 20 bps tailwind from acquisition of VIZIO</p>
</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Adj. operating income (cc)</td>
<td>
<p>Increase 3.5% to 5.5%</p>
<p>•Including approximately 70 bps headwind from lapping leap year</p>
<p>•Including approximately 80 bps headwind from acquisition of VIZIO</p>
</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Interest, net</td>
<td>Increase approximately $100M to $200M</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Effective tax rate</td>
<td>Approximately 23.5% to 24.5%</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Non-controlling interest</td>
<td>Relatively flat</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Adjusted EPS</td>
<td>$2.50 to $2.60, including approximately $0.05 headwind from currency</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Capital expenditures</td>
<td>Approximately 3.0% to 3.5% of net sales</td>
<td>Unchanged</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure></p>


Walmart Affirms FY2026 Adj EPS Guidance of $2.50-$2.60 vs $2.61 Est; Affirms FY2026 Sales Guidance of $694.74B-$701.48B vs $705.33B Est

<p>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.72) by 28.49 percent. This is a 531.43 percent decrease over losses of $(0.35) per share from the same period last year.  The company reported quarterly sales of $29.00 thousand which missed the analyst consensus estimate of $5.00 million by 99.42 percent.  This is a 99.84 percent decrease over sales of $17.58 million the same period last year.</p>


DTIL

Precision BioSciences Q1 EPS $(2.21) Misses $(1.72) Estimate, Sales $29.00K Miss $5.00M Estimate

GAMB

Gambling.com Gr Affirms FY2025 Sales Guidance of $170.00M-$174.00M vs $172.31M Est

<p>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.97) by 17.53 percent. This is a 74.6 percent increase over losses of $(3.15) per share from the same period last year.  The company reported $12.00 thousand in sales this quarter. This is a 97.36 percent decrease over sales of $455.00 thousand the same period last year.</p>


REE Automotive Q4 Adj. EPS $(0.80) Beats $(0.97) Estimate, Sales $12.00K Down From $455.00K YoY

<p>Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) reported quarterly losses of $(4.68) per share which missed the analyst consensus estimate of $(3.44) by 36.05 percent. This is a 81.28 percent increase over losses of $(25.00) per share from the same period last year.  The company reported quarterly sales of $640.92 thousand which missed the analyst consensus estimate of $2.35 million by 72.73 percent.  This is a 52.13 percent decrease over sales of $1.34 million the same period last year.</p>


WKHS

Workhorse Gr Q1 EPS $(4.68) Misses $(3.44) Estimate, Sales $640.92K.

<p>Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.90 by 1.11 percent. This is a 31.88 percent increase over earnings of $0.69 per share from the same period last year.  The company reported quarterly sales of $467.30 million which beat the analyst consensus estimate of $458.60 million by 1.90 percent.  This is a 27.75 percent increase over sales of $365.80 million the same period last year.</p>


Marex Group Q1 Adj. EPS $0.91 Beats $0.90 Estimate, Sales $467.30M Beat $458.60M Estimate

Walmart Q1 US Comp Sales +4.5%

<p>American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.04 by 350 percent. This is a 600 percent decrease over earnings of $0.02 per share from the same period last year.  The company reported quarterly sales of $6.11 million which missed the analyst consensus estimate of $8.63 million by 29.18 percent.  This is a 17.18 percent increase over sales of $5.22 million the same period last year.</p>


American Shared Hospital Q1 EPS $(0.10) Misses $0.04 Estimate, Sales $6.11M Miss $8.63M Estimate

BTDR

Bitdeer Technologies Q1 Adj. EPS $(0.39) Misses $(0.31) Estimate, Sales $70.13M Beat $66.77M Estimate

Walmart Q1 Global eCommerce Sales +22%

Gambling.com Gr Q1 Adj. EPS $0.32 Beats $0.25 Estimate, Sales $40.63M Beat $40.06M Estimate

<p>HC Wainwright &amp; Co.  analyst Matthew Caufield   reiterates Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Buy and maintains $30 price target.</p>


Price Target

Reiteration

Analyst Ratings

ADVM

HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target

<p>Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.58 by 5.17 percent. This is a 1.67 percent increase over earnings of $0.60 per share from the same period last year.  The company reported quarterly sales of $165.61 billion which missed the analyst consensus estimate of $165.88 billion by 0.16 percent.  This is a 2.54 percent increase over sales of $161.51 billion the same period last year.</p>


Walmart Q1 Adj. EPS $0.61 Beats $0.58 Estimate, Sales $165.61B Miss $165.88B Estimate

<p>Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) reported quarterly losses of $(0.09) per share. This is a 94.61 percent increase over losses of $(1.67) per share from the same period last year.  The company reported $165.80 million in sales this quarter. This is a 38.62 percent decrease over sales of $270.12 million the same period last year.</p>


GORV

Lazydays Hldgs Q1 EPS $(0.09) Up From $(1.67) YoY, Sales $165.80M Down From $270.12M YoY

Press Releases

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Legal

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Comments

Septerna

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL